Idexx Laboratories Inc (IDXX) Financials
Key financial figures for Idexx Laboratories Inc (Q3 2026).
IDEXX Q3 2026 revenue rose 10% to $1,214.2 million with CAG Diagnostics recurring revenue up 11% organic, and full-year revenue and EPS guidance were raised. Revenue was $1,214.2 million, up 9.9% reported and 10.0% organic from $1,105.2 million a year earlier; Companion Animal Group (CAG) revenue was $1,116.0 million, up 10.2% reported and 10.4% organic. CAG Diagnostics recurring revenue was $967.4 million, up 10.8% reported and 11.0% organic (U.S. 9.6% organic, International 13.6% organic); IDEXX VetLab consumables grew 14.3% reported and reference laboratory services 10.0%, while rapid assay products grew 0.6% and CAG Diagnostics capital instruments were flat at $51.5 million. On the outlook: 2026 outlook raised: revenue $4,741M-$4,767M (prior $4,700M-$4,745M); reported revenue growth 10.1%-10.8% (prior 9.1%-10.3%); organic growth 9.3%-10.0% (prior 8.5%-9.7%); CAG Diagnostics recurring revenue growth 11.0%-11.7% reported (prior 10.1%-11.3%) and 10.3%-11.0% organic (prior 9.5%-10.7%); EPS $14.96-$15.16 (prior $14.69-$14.94); operating margin lowered to 32.1%-32.3% (prior 32.3%-32.5%), including acquisition-related impacts; free cash flow 95%-100% of net income (prior 90%-100%); capital expenditures ~$160M (prior ~$180M). Figures are for Q3 2026, as IDEXX Laboratories, Inc. reported them.
- Revenue
- $1.2B
- Net Income
- $317M
- EPS
- $4.02
- Total Assets
- $3.7B
- Operating Cash Flow
- $450M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1.2B | $317M | $4.01 | 33.14% | $421M |
| Q2 FY2026 | $1.2B | $338M | $4.27 | 34.98% | $323M |
| Q1 FY2026 | $1.1B | $278M | $3.47 | 31.78% | $234M |
| Q4 FY2025 | $1.1B | $248M | $3.08 | 28.94% | $323M |
| Q3 FY2025 | $1.1B | $275M | $3.40 | 32.11% | $371M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $4.3B | $1.1B | $13.08 | 31.6% | $1.1B |
| FY2024 | $3.9B | $888M | $10.67 | 28.95% | $798M |
| FY2023 | $3.7B | $845M | $10.06 | 29.97% | $773M |
Frequently asked questions
What was IDEXX Laboratories, Inc.'s revenue last quarter?
IDEXX Laboratories, Inc. reported revenue of $1.21 billion for Q3 FY2026, up 9.9% from the same period a year earlier.
Is IDEXX Laboratories, Inc. profitable?
Yes. IDEXX Laboratories, Inc. reported net income of $317.1 million for Q3 FY2026, a net margin of 26.12% on revenue.
How has IDEXX Laboratories, Inc.'s margin trended?
Operating margin was 33.14% in Q3 FY2026, compared with 32.11% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did IDEXX Laboratories, Inc. generate?
IDEXX Laboratories, Inc. generated free cash flow of $420.8 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Idexx Laboratories Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.